1122 GMT - Robert F. Kennedy Jr.'s nomination as Health and Human Services secretary will likely impact vaccine makers and the Food and Drug Administration, Jefferies analysts write. Kennedy has publicly criticized childhood and mRNA-based vaccines, the analysts say. Vaccine perception in the U.S. could suffer, leading to lower demand and sales and potentially cause outbreaks if vaccinations are not consistent over the next four years, Jefferies says. Kennedy has also been vocal on overhauling the FDA, which could alter the regulatory path, resources for biotech and drug review positions as well as impacting key FDA leadership. Bavarian Nordic shares are down 16%, with Valneva down 6%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
November 15, 2024 06:22 ET (11:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。